Business Details
We are the Pediatric Brain Tumor Consortium, a cooperative organization dedicated to improving outcomes for children with primary CNS tumors. Since our founding in 1999, we have accumulated 26 years of collective experience across fifteen leading academic centers and childrens hospitals in the United States and Canada. Our multidisciplinary teams conduct rigorous phase I and II clinical trials that evaluate new therapeutic agents, advanced delivery technologies, and innovative radiation strategies. We employ uniformly highquality statistical science to design studies, analyze data, and ensure that every finding is robust and reproducible. Our collaborative partnership with the Childrens Oncology Group guarantees that promising results are confirmed in larger, phase III trials, advancing the standard of care. We have enrolled more than 2,200 patients and completed 47 therapeutic studies, generating a wealth of evidence that directly informs clinical practice.
In addition to clinical research, we perform correlative tumor biology studies that identify reliable biomarkers and predictors of treatment response. Our laboratory analyses use stateoftheart genomic and proteomic platforms, translating molecular insights into actionable therapeutic strategies. We are committed to transparency, sharing protocols, data, and outcomes with the scientific community and patient families through publications and professional meetings. Our professional standards prioritize patient safety, ethical conduct, and informed consent, ensuring that families receive the highest level of care. We continually strive to deliver timely, innovative solutions that improve survival and quality of life for children battling brain tumors.
In addition to clinical research, we perform correlative tumor biology studies that identify reliable biomarkers and predictors of treatment response. Our laboratory analyses use stateoftheart genomic and proteomic platforms, translating molecular insights into actionable therapeutic strategies. We are committed to transparency, sharing protocols, data, and outcomes with the scientific community and patient families through publications and professional meetings. Our professional standards prioritize patient safety, ethical conduct, and informed consent, ensuring that families receive the highest level of care. We continually strive to deliver timely, innovative solutions that improve survival and quality of life for children battling brain tumors.
Highlights and features
- We have 26 years of research in pediatric brain tumors.
- We have enrolled 2207 patients across 15 leading academic centers.
- We completed 47 therapeutic studies with phase I/II trials.
- We collaborate with the Childrens Oncology Group for confirmatory trials.
- We apply uniformly highquality statistical science to every study.
Services
Phase I/II Trials
Our Phase I/II trials rapidly evaluate new therapeutic agents in children aged infancy to 21 years with primary CNS tumors. Targeting both novel drugs and advanced delivery technologies, we provide clear safety and efficacy data for future confirmatory studies. Families benefit from early access to cuttingedge treatments under rigorous oversight.
Radiation Therapy
Our radiation therapy service employs stateoftheart techniques to target pediatric brain tumors while minimizing damage to healthy tissue. We tailor dose schedules to each childs age, tumor type, and prior treatments, ensuring optimal tumor control. Clinicians rely on our precise planning to improve longterm neurocognitive outcomes.
Biomarker Analysis
Our biomarker analysis identifies predictive and surrogate markers that forecast tumor response to new therapies. Using highthroughput genomic and proteomic platforms, we correlate biomarkers with clinical outcomes across our 47 completed therapeutic studies. This data guides personalized treatment plans and accelerates drug development.
Tumor Biology Research
Our tumor biology research deciphers the molecular mechanisms driving pediatric CNS tumors. Collaborating with 15 academic centers, we analyze patient specimens to discover novel therapeutic targets and resistance pathways. Findings are published in peerreviewed journals, informing nextgeneration clinical trial designs.
